|
**Overview**: Neuronal Autoantibodies Advanced Panel**Introduction**: The Neuronal Autoantibodies Advanced Panel is a diagnostic tool designed for comprehensive paraneoplastic screening using serum samples. In India, expanded paraneoplastic antibody testing detects rare antibodies (anti-Ma2, anti-SOX1, anti-GAD65) in addition to classic ones, associated with diverse neurological syndromes and underlying cancers (small cell lung, thymoma, testicular). High morbidity from incomplete testing in rural/low-SES patients with subacute encephalomyelitis or cerebellar ataxia, limited advanced labs, delayed tumor identification and immunotherapy leading to irreversible deficits. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs immunoassay for 9 neuronal autoantibodies over 1-2 days with high specificity, valuable for broad PNS diagnosis. This diagnostic falls under autoimmune screening and targets patients with atypical neurological syndromes or high cancer suspicion, addressing accurate detection to guide extensive tumor search and immunomodulation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise antibody profiling and improving PNS outcomes. Its serum-based approach ensures reliable multi-antibody detection.**Other Names**: Neuronal Adv Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded paraneoplastic panel standard; in India, used in tertiary neuro centers.**Purpose**: The test assesses 9 parameters including anti-Hu to guide comprehensive PNS screening, detect rare antibodies, inform tumor search.**Test Parameters**: 1. Anti-Hu, 2. Anti-Ri, 3. Anti-Yo, 4. Anti-CV2, 5. Anti-PNMA2, 6. Anti-Amphiphysin, 7. Anti-Ma2, 8. Anti-SOX1, 9. Anti-GAD65.**Pretest Condition**: No fasting required; patients should have subacute neurological symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on neurological progression, cancer risk.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected PNS including deficits, benefits of advanced screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive rare antibody (e.g., anti-Ma2) indicates specific PNS/cancer association, necessitating specialist input.**Specialist Consultation**: Neurologists or neuro-oncologists should be consulted for management.**Additional Supporting Tests**: CSF autoantibodies, whole-body PET-CT for confirmation.**Test Limitations**: Not all PNS antibody-positive; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Paraneoplastic Studies India 2023. |
